Adjuvant trastuzumab for breast cancer: Advent of pharmacogenetics raises many issues

doi:10.1136/bmj.331.7526.1202-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Hazel Thornton (hazelcagct@keme.co.uk), honorary visiting fellow

Department of Health Sciences, University of Leicester “Saionara,” Colchester CO5 7EA

EDITOR—Kell and Power [previous letter] at last clarify for everyone that at least 20% of patients with positive immunochemical results will not benefit from trastuzumab.1 These are expensive false positives at £20 000 yearly per patient, both for the health system and for patients' quality of life—or, indeed, life at all, bearing in mind the death rate …